Business
US Cystic Fibrosis Therapeutics Market Forecast and Company Analysis Report 2025-2033 Featuring Vertex, Abbvie, Novartis, Gilead Sciences, Viatris, Pfizer, AstraZeneca, and F. Hoffmann-La Roche
The United States Cystic Fibrosis Therapeutics Market is set to grow from an estimated US$ 2.32 billion in 2024 to US$ 4.72 billion by 2033, with an 8.22% CAGR from 2025 to 2033. This growth is driven by advancements in gene therapy, increased access to CFTR modulators, and robust research initiatives. Key players like Vertex Pharmaceuticals and Abbvie leverage developments like Trikafta, expanding the therapeutic market. Challenges including high treatment costs and limited rural access persist
About this update from Vertex Pharmaceuticals Incorporated
[{"type":"image","alt":"Company Logo","displaySize":"","headline":null,"caption":"Company Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":36,"url":"https://media.zenfs.com/en/globenewswire.com/6a90a26a88cc04ec0d3fe15e0ab1be65"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/g_3H8YP5.WdAX5cBtX03VA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTUwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/6a90a26a88cc04ec0d3fe15e0ab1be65","width":300,"height":36}},"lazy":false},{"type":"text","content":"The United States Cystic Fibrosis Therapeutics Market is set to grow from an estimated US$ 2.32 billion in 2024 to US$ 4.72 billion by 2033, with an 8.22% CAGR from 2025 to 2033. This growth is driven by advancements in gene therapy, increased access to CFTR modulators, and robust research initiatives. Key players like Vertex Pharmaceuticals and Abbvie leverage developments like Trikafta, expanding the therapeutic market. Challenges including high treatment costs and limited rural access persist, while states like California and New York lead in market demand and innovation. Advocacy organizations and healthcare infrastructure sustain this dynamic market environment.","length":675,"tagName":"p"},{"type":"text","content":"U.S. Cystic Fibrosis Therapeutics Market","length":40,"tagName":"p"},{"type":"image","alt":"U.S. Cystic Fibrosis Therapeutics Market","displaySize":"","headline":null,"caption":"U.S. Cystic Fibrosis Therapeutics Market","credit":"GlobeNewswire Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":600,"height":400,"url":"https://media.zenfs.com/en/globenewswire.com/bbd347c35cc79a889f6d26b4ba874682"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/WcCTXR_piCDywIKCa.4Zew--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTY0MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/bbd347c35cc79a889f6d26b4ba874682","width":600,"height":400}}},{"type":"text","content":"Dublin, Sept. 10, 2025 (GLOBE NEWSWIRE) -- The "United States Cystic Fibrosis Therapeutics Market to See Strong Growth Through 2033 - Driven by Gene Therapy and CFTR Innovation" report has been added to ResearchAndMarkets.com's offering.The United States Cystic Fibrosis Therapeutics Market is expected to reach US$ 2.32 billion in 2024 and further reach US$ 4.72 billion by the end of 2033 at a compound annual growth rate of ...